Aptevo Therapeutics APVO
NASDAQ APVO
$1.62 +0.00 (+0.31%)
As of: Oct 21, 2026 · 1:36 PM EDT

Aptevo Therapeutics (APVO) Current Deferred Revenue (2015 - 2017)

Updated

Aptevo Therapeutics' Current Deferred Revenue came in at $1.44 million for Q2 2017, up 266.5% from $394,000 a year earlier and up 64.5% from the prior quarter.

Analysis

Aptevo Therapeutics (APVO) Current Deferred Revenue (2015 - 2017) Analysis & Trends

At the end of FY2016, Aptevo Therapeutics' Current Deferred Revenue was $811,000, down 78.9% from FY2015.

  • Going back by year, Current Deferred Revenue was $3.84 million in FY2015.
  • The Q2 2017 figure represents the highest quarterly Current Deferred Revenue since Q4 2015.
  • Business Quant data shows APVO's Current Deferred Revenue at $878,000 (Q1 2017), $811,000 (Q4 2016) and $640,000 (Q3 2016) in the three quarters before Q2 2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Aptevo Therapeutics 1.94 Mn -65.06 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 1.44 Mn
Mar 31, 2017 878,000.00
Dec 31, 2016 811,000.00
Sep 30, 2016 640,000.00
Jun 30, 2016 394,000.00
Dec 31, 2015 3.84 Mn
API Access

Aptevo Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=APVO&period=max&api_key=YOUR_API_KEY